AssetMark Inc
GMAB icon

AssetMark Inc’s Genmab GMAB Stock Holding History

AssetMark Inc’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.56M Buy
238,803
+14,659
+7% +$390K 0.01% 659
2026
Q1 		$6.01M Sell
224,144
-9,708
-4% -$291K 0.01% 621
2025
Q4 		$7.2M Buy
233,852
+224,586
+2,424% +$7M 0.01% 571
2025
Q3 		$284K Buy
9,266
+9,050
+4,190% +$221K ﹤0.01% 1194
2025
Q2 		$4.46K Sell
216
-2
-0.9% -$41 ﹤0.01% 2165
2025
Q1 		$4.27K Sell
218
-17,891
-99% -$375K ﹤0.01% 2029
2024
Q4 		$378K Sell
18,109
-64,520
-78% -$1.42M ﹤0.01% 996
2024
Q3 		$2.01M Buy
82,629
+11,519
+16% +$308K 0.01% 652
2024
Q2 		$1.79M Buy
71,110
+5,885
+9% +$167K 0.01% 642
2024
Q1 		$1.95M Buy
65,225
+21,707
+50% +$638K 0.01% 590
2023
Q4 		$1.39M Buy
43,518
+2,636
+6% +$82.8K 0.01% 600
2023
Q3 		$1.44M Buy
40,882
+4,021
+11% +$153K 0.01% 559
2023
Q2 		$1.4M Buy
36,861
+7,556
+26% +$301K 0.01% 550
2023
Q1 		$1.11M Buy
29,305
+4,318
+17% +$166K ﹤0.01% 584
2022
Q4 		$1.06M Sell
24,987
-371
-1% -$15.3K ﹤0.01% 558
2022
Q3 		$815K Buy
25,358
+5,993
+31% +$210K ﹤0.01% 559
2022
Q2 		$629K Buy
19,365
+6,691
+53% +$217K ﹤0.01% 594
2022
Q1 		$459K Buy
12,674
+4,193
+49% +$144K ﹤0.01% 628
2021
Q4 		$336K Sell
8,481
-39,573
-82% -$1.65M ﹤0.01% 612
2021
Q3 		$2.1M Buy
48,054
+4,254
+10% +$191K 0.01% 325
2021
Q2 		$1.79M Buy
43,800
+14,526
+50% +$561K 0.01% 332
2021
Q1 		$961K Buy
29,274
+2,426
+9% +$91.2K 0.01% 366
2020
Q4 		$1.09M Buy
26,848
+8,385
+45% +$313K 0.01% 344
2020
Q3 		$676K Buy
18,463
+15,302
+484% +$553K ﹤0.01% 372
2020
Q2 		$107K Sell
3,161
-861
-21% -$23.5K ﹤0.01% 574
2020
Q1 		$85K Sell
4,022
-1,279
-24% -$28.5K ﹤0.01% 597
2019
Q4 		$118K Buy
5,301
+1,180
+29% +$25.8K ﹤0.01% 607
2019
Q3 		$83K Buy
+4,121
New +$81.2K ﹤0.01% 638

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AssetMark Inc's GMAB Position: Q2 2026 in Review

AssetMark Inc increased its Genmab (GMAB) stake by 6.5% in Q2 2026, buying an estimated $390K and bringing the position to 238,803 shares worth $6.56M. The position accounts for 0.01% of the portfolio, ranked #659.

AssetMark Inc first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $7.2M in Q4 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • AssetMark Inc held 238,803 shares of Genmab worth $6.56M as of Q2 2026.
  • AssetMark Inc bought 14,659 Genmab shares in Q2 2026, an estimated $390K.
  • Genmab made up 0.01% of AssetMark Inc's portfolio in Q2 2026, its #659 holding.
  • AssetMark Inc first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • AssetMark Inc's Genmab position peaked at $7.2M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.